semaglutide sodium Peptide of the Week: Peptide: A Promising Advancement in Diabetes Treatment Weight Loss & Infusions -

The $600 billion drugmaker behind the weight loss medication Ozempic has lobbied Australian authorities to block pharmacists making copycat medications despite low supply of the hugely popular drug

pharmacy, ensuring the highest standards of safety and efficacy

Tirzepatide is a dual GIP and GLP-1 receptor agonist and the active ingredient in FDA-approved medications such as Mounjaro and Zepbound

Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart Failure

Adipose tissue is chronically inflamed in obesity owing to pre-adipocyte expansion and activation of nuclear factor-B (NF-B), which upregulate pro-inflammatory cytokines